The CDMO is channeling new capital toward ongoing efforts to shift operations to biologics and aseptic drug production at its core sites in Cincinnati and Toronto.
The collaboration will combine U.S. and South Korean CDMO networks to deliver integrated ADC manufacturing services and strengthen supply chain resilience.
